These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 7578708)

  • 21. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia.
    Leucht S; Heres S
    J Clin Psychiatry; 2006; 67 Suppl 5():3-8. PubMed ID: 16822090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Overcoming resistance to therapy in schizophrenia].
    Poliachenko AB; Mogilianskaia FN
    Vrach Delo; 1985 Aug; (8):110-1. PubMed ID: 2866630
    [No Abstract]   [Full Text] [Related]  

  • 23. A clinician with a family member with schizophrenia: a case report.
    Hough G
    Bull Menninger Clin; 1995; 59(3):345-56. PubMed ID: 7550059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The risk of rehospitalisation during therapy with atypical and typical neuroleptics--a contribution to differential indication].
    Müller P; Nerenz H; Schaefer E
    Psychiatr Prax; 2002 Oct; 29(7):388-91. PubMed ID: 12378421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to prescribe an APAP?].
    Dassa D; Lacambre M; Vacheron MN
    Encephale; 2009 Jan; Suppl 3():S109-13. PubMed ID: 19268179
    [No Abstract]   [Full Text] [Related]  

  • 26. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia.
    Dursun S
    J Psychopharmacol; 2005 Sep; 19(5 Suppl):3-4. PubMed ID: 16144780
    [No Abstract]   [Full Text] [Related]  

  • 27. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals.
    Day JC; Bentall RP; Roberts C; Randall F; Rogers A; Cattell D; Healy D; Rae P; Power C
    Arch Gen Psychiatry; 2005 Jul; 62(7):717-24. PubMed ID: 15997012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.
    Wehmeier PM; Kluge M; Schacht A; Helsberg K; Schreiber W; Schimmelmann BG; Lambert M
    J Psychiatr Res; 2008 Jul; 42(8):676-83. PubMed ID: 17720192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Longterm therapy of schizophrenia].
    Pajonk FG; Wobrock T; Falkai P
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):161-74; quiz 175-7. PubMed ID: 15747226
    [No Abstract]   [Full Text] [Related]  

  • 30. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to evaluate the quality of observations].
    Benoit M; Pon J; Zimmermann MA
    Encephale; 2009 Jan; Suppl 3():S87-90. PubMed ID: 19268184
    [No Abstract]   [Full Text] [Related]  

  • 31. [Expert opinion on APAP (Prolonged action atypical antipsychotic agents). Conclusion].
    Guelfi JD
    Encephale; 2009 Jan; Suppl 3():S123-4. PubMed ID: 19268182
    [No Abstract]   [Full Text] [Related]  

  • 32. [Problems with the treatment of schizophrenics in the doctor's office].
    Sielk M
    MMW Fortschr Med; 2003 May; 145 Suppl 2():22-6. PubMed ID: 14579480
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pharmacological standards in schizophrenia treatment].
    Jarema M; Kiejna A; Landowski J; Meder J; Jolanta RJ; Rybakowski J
    Psychiatr Pol; 2006; 40(6):1171-205. PubMed ID: 17444297
    [No Abstract]   [Full Text] [Related]  

  • 34. What are the nursing implications when using paliperidone prolonged release for people with schizophrenia.
    Jones A
    J Psychiatr Ment Health Nurs; 2008 Dec; 15(10):792-9. PubMed ID: 19012670
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). Foreword].
    Guelfi JD; Costentin J; Terra JL
    Encephale; 2009 Jan; Suppl 3():S85-6. PubMed ID: 19268183
    [No Abstract]   [Full Text] [Related]  

  • 36. Atypical neuroleptics in the treatment of early onset schizophrenia.
    Masi G
    Panminerva Med; 1997 Sep; 39(3):215-21. PubMed ID: 9360425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neuroleptic treatment of patients with schizophrenia. Mechanisms of action and clinical significance.
    Wiesel FA
    Br J Psychiatry Suppl; 1994 Apr; (23):65-70. PubMed ID: 7913610
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survey of the adjuvant use of benzodiazepines for treating outpatients with schizophrenia.
    Pecknold JC
    J Psychiatry Neurosci; 1993 Mar; 18(2):82-4. PubMed ID: 8096393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Expert opinion on APAP (prolonged action atypical antipsychotic agents). How to make the decision to resort to an APAP)].
    Chéreau I; Gorwood P; Mouchabac S
    Encephale; 2009 Jan; Suppl 3():S97-100. PubMed ID: 19268186
    [No Abstract]   [Full Text] [Related]  

  • 40. Capacity assessment and intervention in 56-yr-old man with schizophrenia.
    Schlechter A
    Mt Sinai J Med; 2008; 75(2):153-5. PubMed ID: 18500718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.